Latest Conference Articles

I. Paul Singh, MD, sat down with David Hutton of Ophthalmology Times to discuss his poster "Travoprost Intraocular Implant Demonstrates Efficacy in Diverse Subpopulations of OAG and OHT Subjects," from the American Glaucoma Society meeting held in Huntington Beach

Leon Herndon, MD, President of the American Glaucoma Society, sat down with David Hutton of Ophthalmology Times to discuss the AGS meeting held in Huntington Beach and what attendees can expect as well as new and exciting information to come from the meeting.

Neda Shamie, MD, highlights the origins and growth of CIME and what makes it unique from other meetings.

Anthony Mai, MD, shared results from using the miCOR 700 device, which is a new device from Zeiss, for phacoemulsification cataract surgery at the EnVision Summit 2024. He spoke with Peg Achenbach, OD, FAAO, Executive Director/Global Ambassador Strategies, Ophthalmology and Optometry at MJH Life sciences, on location in Puerto Rico to share more about his presentation.

Cutting-edge advances are outlined at Hawaiian Eye and Retina 2024

The prevailing message is that physicians have “a long way to go” in the optimization of management and prevention of myopic vitreoretinal disease.

Sruthi Arepalli, MD, discusses the case of a patient with syphilis and sheds light on the complexities of diagnosing a masquerading syndrome.

Marsha Link, PhD, uses three words—Imagine, Prepare, and Optimize—to encourage women to assess their current leadership journey, strategically plan for advancement, and explore new opportunities for growth and impact in vision care.

Marsha Link, PhD, uses three words—Imagine, Prepare, and Optimize—to encourage women to assess their current leadership journey, strategically plan for advancement, and explore new opportunities for growth and impact in vision care.

The 2024 EnVision Summit will feature a brand-new Optometry Program, co-chaired by Danica Marrelli, OD, FAAO, AAO Dipl, and Cecelia Koetting, OD, FAAO, DipABO.

The event, being held at the El Conquistador Resort in Puerto Rico, is offering programs for ophthalmologists and optometrists.

Robert L Stamper, MD, raises the question of physician liability for allowing the patient to drive.

Shan C. Lin, MD, discusses combined minimally invasive glaucoma surgery and its impact on achieving improved intraocular pressure efficacy.

Joseph Panarelli, MD, sat down with David Hutton of Ophthalmology Times to discuss the panel he moderated at the Glaucoma 360 meeting held in San Francisco, about innovations in glaucoma drugs, and drug delivery.

Adrienne Graves, PhD, and Andrew Iwach, MD, co-founders of Glaucoma 360, highlight the 13th annual Glaucoma 360 New Horizons Forum, held this year at the Westin St. Francis San Francisco on Union Square.

Tonian McDonald shares her story during the Glaucoma 360 New Horizons Forum at the Westin St. Francis Hotel in San Francisco to recount her journey as a glaucoma patient.

Hoskins was a pioneer and leader in the field of ophthalmology and glaucoma, and served as executive vice president of the American Academy of Ophthalmology, founding director and Director Emeritus of the Glaucoma Research Foundation, and a founding director of the American Glaucoma Society.

Dr Baruch Kuppermann discusses interim results from the first in-human Phase 2 RIPPLE-1 Trial of a dexamethasone implant for diabetic macular oedema and retinal vein occlusion.

Baruch Kuppermann, MD, PhD, discusses interim results from the first in-human Phase 2 RIPPLE-1 Trial of a dexamethasone implant for diabetic macular edema and retinal vein occlusion.

Ramin Tadayoni, MD, PhD, highlights data from the BALATON and COMINO Phase 3 studies about faricimab

Ramin Tadayoni, MD, PhD, highlights data from the BALATON and COMINO Phase 3 studies about faricimab, respectively, in branch retinal vein occlusion and central retinal vein occlusion.

Robyn Guymer, MBBS, PhD, reported the Voyager study’s preliminary data at the 2024 Angiogenesis, Exudation, and Degeneration conference

A minimum of 5,000 patients with up to 5 years of follow-up will be included in the study, with patients from a variety of practice settings and clinician experiences in 28 countries and 500 sites

Jennifer I. Lim, MD, FARVO, FASRS sat down with Hattie Hayes of Ophthalmology Times Europe to discuss her findings, including exciting advancements in targeting Ang2 and VEGF from the Angiogenesis Exudation and Degeneration 2024 event.

Dr. Jennifer Lim reveals new data on Angiopoietin-2 inhibition as a target for addressing nAMD and DME.